This 2008 study investigated the interactions between vitamin C (ascorbic acid) and intravenous (IV) iron formulations, specifically iron sucrose (FeSuc) and ferric gluconate (FeGlu). The researchers found that both FeSuc and FeGlu accelerated the oxidation of vitamin C in human plasma and whole blood, with FeSuc exhibiting a higher oxidative
This 1982 study investigated the relationship between serum zinc levels and T-lymphocyte function in 13 long-term hemodialysis patients. Six patients exhibited depressed T-cell mitogen responses and had lower mean serum zinc concentrations (63 ± 11 µg/dL) compared to seven patients with normal responses (75 ± 14 µg/dL). However, no significant
This study investigated the effect of folic acid (B9) and vitamin B12 supplementation on lowering plasma total homocysteine (tHcy) levels in hemodialysis (HD) patients, specifically focusing on the impact of MTHFR (C677T) genotypes. It involved 132 HD patients who were randomized to receive B9, B12, or a combination of both
This study examines the relationship between fibrinogen levels, lipids, and cardiovascular disease (CVD) risk in patients with chronic renal disease. Fibrinogen, a protein elevated during inflammation, was significantly higher in patients with renal disease compared to healthy controls. The study found a strong correlation between fibrinogen levels, diastolic blood pressure,
This randomized controlled trial investigated the effects of intravenous L-carnitine supplementation on plasma carnitine levels, fatigue, and exercise capacity in hemodialysis patients over 24 weeks. L-carnitine significantly increased plasma carnitine concentrations and was associated with a smaller decline in peak oxygen consumption (VO₂max) compared to placebo (-0.05 ± 0.19 vs.
This randomized controlled trial examined the effects of intravenous L-carnitine supplementation on fatigue and exercise capacity in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Patients received L-carnitine at doses of 10 mg/kg, 20 mg/kg, or 40 mg/kg thrice weekly for 24 weeks. While primary analysis showed no significant improvement
This observational study examined the effects of intravenous L-carnitine on myocardial fatty acid metabolism in hemodialysis patients, with the goal of identifying responders and non-responders to the treatment. The study found that intravenous L-carnitine increased plasma carnitine levels, reduced fatigue, and helped maintain peak exercise capacity in patients. These results
